We are cutting-edge Health Tech company specializing in connecting vast molecular biology with novel photonics technologies, chemistry & biomedical engineering to create biosensing solutions that can revolutionize infectious diseases in-vitro diagnostics.
We discover, develop and commercialize disruptive diagnostics and monitoring tools on a global scale and create lifesaving innovations which can help medical professionals in real-time diagnosis and monitoring.
FIBIOMED SPÓŁKA z o.o. (LLC) is undertaking the project titled:
"Development and testing of an innovative technology to cultivate specific antibodies, and a device for fast diagnostics of viruses (including SARS-Cov-2) that can be implemented in the diagnostics, treatment and prevention during states of epidemiological emergency, as part of Measure 1.1 “R+D Projects of Enterprises” and Sub-Measure 1.1.1 “Industrial Research and Development Works Conducted by Enterprises”
The objective of the project is to develop, test and implement an innovative partly automated device for high-throughput analysis of samples for SARS-CoV-2 that can be easily and quickly adapted to the analysis of other pathogens or diagnostic markers.
Project value: PLN 12,327,736.88
Contribution of European Funds: PLN 10,046,456.53
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2020
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was FiBioMed founded?
FiBioMed was founded in 2020.
What industry is FiBioMed in?
FiBioMed operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is FiBioMed based?
FiBioMed is headquartered in Lublin, Poland.
Find investors for your startup like FiBioMed
Gritt sends AI-personalised outreach to each investor — from your Gmail
